Existing and future pharmacotherapy for erectile dysfunction

Bibliography

• BENET AE, MELMAN A: The epidemiology of erectile dysfunction. Urol. Clin. North Am. (1995) 22:699-709.
   PubMed Web of Science ®Google Scholar
• AYTA IA, MCKINLAY JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. (1999) 84:59-56.
   Google Scholar
• CARSON CC, LUE TF: Phosphodiesterase 5 inhibitors for erectile dysfunction. BJU Int. (2005) 96:257- 280.
   PubMed Web of Science ®Google Scholar
• MONTORSI F, PERANI D, ANCHISI D et al.: Brain activation patterns during video sexual stimulation following the administration apomorphine: results of a placebo-controlled study. Eur. Urol. (2003) 43(4):405-411.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, WAGNER G: Physiology of penile erection. Physiol. Rev. (1995) 75(1):191-236.
   PubMed Web of Science ®Google Scholar
• RAJFER J, ARONSON WJ, BUSH PA, DOREY FJ, IGNARRO LJ: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. (1992) 326:90-94.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, HOLMQUIST F: Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J. Urol. (1994) 12(5):249-261.
   PubMed Web of Science ®Google Scholar
• MAGEE T, FUENTES AM, GARBAN H et al.: Cloning of a novel neuronal nitric oxide synthase expressed in penis and lower urinary tract. Biochem. Biophys. Res. Commun. (1996) 226:145-151.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-CADAVID NF, RAJFER J: The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr. Pharm. Des. (2005) 11(31):4041-4046.
   PubMed Web of Science ®Google Scholar
• FAN SF, BRINK PR, MELMAN A, CHRIST GJ: An analysis of the Maxi-K+ (KCa) channel in cultured human corporal smooth muscle cells. J. Urol. (1995) 153:818-825.
   PubMed Web of Science ®Google Scholar
• BALLARD SA, GINGELL CJ, TANG K, TURNER LA, PRICE ME, NAYLOR AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities cyclic nucleotide phosphodiesterase isoenzymes. J. Urol. (1998) 159:2164-2171.
   PubMed Web of Science ®Google Scholar
• PORST H: The rationale for prostaglandin E1 in erectile failure: a survey of world wide experience. J. Urol. (1996) 155:802-815.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE: Pharmacology of Penile Erection. Pharmacol. Rev. (2001) 53:417-450.
   PubMed Web of Science ®Google Scholar
• MORELAND RB, HSIEH G, NAKANE M, BRIONI JD: The biochemical and neurologic basis for the treatment of male erectile dysfunction. J. Pharmacol. Exp. Ther. (2001) 296:225-234.
   PubMed Web of Science ®Google Scholar
• TEMEL Y, HAFIZI S, BEULS E, VISSER-VANDEWALLE V: The supraspinal network in the control of erection. Expert Opin. Ther. Targets (2005) 5:941-954.
   Google Scholar
• MELIS MR, ARGIOLAS A: Dopamine and sexual behavior. Neurosci. Biobehav. Rev. (1999) 19:19-38.
   Google Scholar
• DULA E, KEATING W, SIAMI PF et al.: Efficacy and safety of fixed dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction: the Apomorphine Study Group. Urology (2000) 56(1):130-135.
   PubMed Web of Science ®Google Scholar
• MARTINEZ R, PUIGVERT A, POMEROL JM, RODRIGUEZ-VILLALBA R: Clinical experience with apomorphine hydrochloride: the first 107 patients. J. Urol. (2003) 170(6 Pt 1):2352-23525.
   PubMed Web of Science ®Google Scholar
• PERIMENIS P, GYFTOPOULOS K, GIANNITSAS K et al.: A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int. J. Imp. Res. (2004) 16:2-7.
   PubMed Web of Science ®Google Scholar
• PERIMENIS P, MARKOU S, GYFTOPOULOS K et al.: Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Andrologia (2004) 36:106-110.
   PubMed Web of Science ®Google Scholar
• DULA E, BUKOFZER S, PERDOK R, GEORGE M: Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur. Urol. (2001) 39(5):558-563.
   PubMed Web of Science ®Google Scholar
• BERTOLINI A, GESSA GL: Behavioral effects of ACTH and MSH peptides. J. Endocrinol. Invest. (1981) 42:241-251.
   Google Scholar
• WESSELLS H, BLEVINS JE, VANDERAH TW: Melanocortinergic control of penile erection. Peptides (2005) 26(10):1972-1977.
   PubMed Web of Science ®Google Scholar
• WESSELLS H, LEVINE N, HADLEY ME, DORR R, HRUBY V: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. Int. J. Impot. Res. (2000) 12(Suppl 4):S74-S79.
   Google Scholar
• DIAMOND LE, EARLE DC, ROSEN RC, WILLETT MS, MOLINOFF PB: Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int. J. Impot. Res. (2004) 16(1):51-59.
   PubMed Web of Science ®Google Scholar
• ROSEN RC, DIAMOND LE, EARLE DC, SHADIACK AM, MOLINOFF PB: Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int. J. Impot. Res. (2004) 16(2):135-142.
   PubMed Web of Science ®Google Scholar
• SEBHAT IK, MARTIN WJ, YE Z et al.: Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J. Med. Chem. (2002) 45(21):4589-4593.
   PubMed Web of Science ®Google Scholar
• MARTIN WJ, MCGOWAN E, CASHEN DE et al.: Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula. Eur. J. Pharmacol. (2002) 454(1):71-79.
   PubMed Web of Science ®Google Scholar
• CHEN J, WOLLMAN Y, CHERNICHOVSKY T, IAINA A, SOFER M, MATZKIN H: Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int. (1999) 83(3):269-273.
   PubMed Web of Science ®Google Scholar
• GARBAN H, MARQUEZ D, MAGEE T et al.: Cloning of rat and human inducible penile nitric oxide synthase. Application of gene therapy for erectile dysfunction. Biol. Reprod. (1997) 56:954-963.
   PubMed Web of Science ®Google Scholar
• MAGEE T, FERRINI M, GARBAN H et al.: Gene therapy for erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol. Reprod. (2002) 67:1033-1041.
   PubMed Web of Science ®Google Scholar
• BIVALACQUA TJ, USTA MF, CHAMPION HC et al.: Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int. J. Impot. Res. (2004) 16:21-29.
   PubMed Web of Science ®Google Scholar
• BURNETT AL: Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction? Urology (2005) 65(2):224-230.
   PubMed Web of Science ®Google Scholar
• OMORI K, KOTERA J, MOCHIDA H et al.: Avanafil has the potential for the treatment of erectile dysfunction with selective phosphodiesterase-5 inhibition. Proccedings of the 8th Congress of European Society of Sexual Medicine. Copenhagen, Denmark (2005) MP-05-140.
   Google Scholar
• YU JY, KANG KK, YOO M: Erectile potentials of a new phosphodiesterase type 5 inhibitor, DA-8159, in diet-induced obese rats. Asian J. Androl. (2006) 8(3):325-329.
   PubMed Web of Science ®Google Scholar
• KANG KK, YU JY, YOO M, KWON JW: The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int. J. Impot. Res. (2005) 17(5):409-416.
   PubMed Web of Science ®Google Scholar
• KIM JJ, KIM SW, YANG DY: A Phase III study to evaluate the efficacy and safety of udenafil in Korean ED patients. Proccedings of the 8th Congress of European Society of Sexual Medicine. Copenhagen, Denmark (2005) MP-05-249.
   Google Scholar
• KALSI JS, RALPH DJ, THOMAS P et al.: A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. J. Sex. Med. (2005) 2(1):53-57.
   PubMed Web of Science ®Google Scholar
• QIU Y, BHATTACHARJEE S, KRAFT P et al.: JNJ-10280205 and JNJ-10287069: novel PDE5 inhibitors as clinical candidates for erectile dysfunction. Int. J. Impot. Res. (2006) (In Press).
   PubMedGoogle Scholar
• KO FN, WU CC, KUO SC, LEE FY, TENG CM: YC-1, a novel activator of platelet guanylate cyclase. Blood (1994) 84(12):4226-4233.
   PubMed Web of Science ®Google Scholar
• WU CC, KO FN, KUO SC, LEE FY, TENG CM: YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br. J. Pharmacol. (1995) 116(3):1973-1978.
   PubMed Web of Science ®Google Scholar
• WOHLFART P, MALINSKI T, RUETTEN H et al.: Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br. J. Pharmacol. (1999) 128(6):1316-1322.
   PubMed Web of Science ®Google Scholar
• FRIEBE A, MULLERSHAUSEN F, SMOLENSKI A, WALTER U, SCHULTZ G, KOESLING D: YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol. (1998) 54(6):962-967.
   PubMed Web of Science ®Google Scholar
• MIZUSAWA H, HEDLUND P, BRIONI JD, SULLIVAN JP, ANDERSSON KE: Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J. Urol. (2002) 167(5):2276-2281.
   PubMed Web of Science ®Google Scholar
• STASCH JP, BECKER EM, ALONSO-ALIJA C: NO-independent regulatory site on soluble guanylate cyclase. Nature (2001) 410(6825):212-215.
   PubMed Web of Science ®Google Scholar
• STRAUB A, STASCH JP, ALONSO-ALIJA C: NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. (2001) 11(6):781-784.
   PubMed Web of Science ®Google Scholar
• BISCHOFF E, SCHRAMM M, STRAUB A, FEURER A, STASCH JP: BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology (2003) 61(2):464-467.
   PubMed Web of Science ®Google Scholar
• MILLER LN, NAKANE M, HSIEH GC: A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. (2003) 72(9):1015-1025.
   PubMed Web of Science ®Google Scholar
• MILLS TM, CHITALEY K, WINGARD CJ, LEWIS RW, WEBB RC: Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J. Appl. Physiol. (2001) 296:225-234.
   Google Scholar
• SOLMYO AP, SOLMYO AV: Ca2+ sensitivity of smooth muscle and nonmuscle myosin II modulated by G-proteins, kinases and myosin phosphatase. Physiol. Rev. (2003) 83:1325- 1358.
   PubMed Web of Science ®Google Scholar
• REES RW, ZIESSEN T, RALPH DJ, KELL P, MONCADA S, CELLEK S: Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int. J. Impot. Res. (2002) 14:1-7.
   PubMed Web of Science ®Google Scholar
• CHITALEY K, WINGARD CJ, CLINTON WR: Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide- independent pathway. Nat. Med. (2001) 7:119-122.
   PubMed Web of Science ®Google Scholar
• CHITALEY K, BIVALACQUA TJ, CHAMPION HC et al.: Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem. Biophy. Res. Commun. (2002) 298:427-432.
   PubMed Web of Science ®Google Scholar
• LINDER AE, WEBB RC, MILLS TM, YING Z, LEWIS RW, TEIXEIRA CE: Rho-kinase and RGS-containing RhoGEFs as molecular targets for the treatment of erectile dysfunction. Cur. Pharm. Des. (2005) 11:4029- 4040.
   PubMed Web of Science ®Google Scholar
• LINET OI, OGRINC FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N. Engl. J. Med. (1996) 334(14):873-877.
   PubMed Web of Science ®Google Scholar
• PORST H, BUVAT J, MEULEMAN E, MICHAL V, WAGNER G: Intracavernous alprostadil alfadex: an effective and well tolerated treatment for erectile dysfunction: results of a long-term European study. Int. J. Impot. Res. (1998) 10(4):225-231.
   PubMed Web of Science ®Google Scholar
• BECHARA A, CASABE A, CHELIZ G et al.: Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J. Urol. (1997) 157(6):2132-2134.
   PubMed Web of Science ®Google Scholar
• BENNETT AH, CARPENTER AJ, BARADA JH: An improved vasoactive drug combination for a pharmacological erection program. J. Urol. (1991) 146(6):1564-1565.
   PubMed Web of Science ®Google Scholar
• MCMAHON CG: A comparison of the response to the intra-cavernosal injection of papaverine and phentolamine, prostaglandin E1 and a combination of all three agents in the management of impotence. Int. J. Impot. Res. (1991) 3:113-121.
   Google Scholar
• MELMAN A, BAR-CHAMA N, MCCULLOUGH A, DAVIES K, CHRIST G: The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur. Urol. (2005) 48(2):314-318.
   PubMed Web of Science ®Google Scholar